Rimegepant Pharma Grade API, identified by CAS 1289023-67-1 and molecular formula C28H28F2N6O3 with a molecular weight of 534.56 g/mol, is a small-molecule calcitonin gene-related peptide receptor antagonist supplied for pharmaceutical processing into tablet, capsule, granule, and injectable dosage forms. The free base exhibits low aqueous solubility and pH-dependent dissolution behaviour; the sulfate salt is the form used in the commercially available orally disintegrating tablet, where rapid dispersion and dissolution are critical. Two process grades are defined: an oral grade for tablet, capsule, and granule processing, and an injectable grade with reduced bioburden and endotoxin controls. The certificate of analysis must state whether the assay is expressed on the free base or sulfate salt basis. The material is controlled as a single enantiomer with defined stereocenters, and the crystalline state is monitored by X-ray powder diffraction because amorphous conversion changes dissolution kinetics. Oral grades are released with controls for assay, related substances, residual solvents, water, and particle size distribution; injectable grades additionally require bacterial endotoxin, bioburden, and sub-visible particulate matter controls aligned with parenteral expectations. The API is manufactured under ICH Q7 GMP, and specification selection follows ICH Q6A decision trees with methods referenced to general chapters in USP and Ph. Eur. where applicable.

Specification Framework and Particle-Size-Dependent Release Controls

A representative oral-grade release specification begins with appearance and identification. Identification is confirmed by infrared absorption matching a reference spectrum and by HPLC retention time correlation with a certified standard. Assay is determined by stability-indicating HPLC and is typically controlled within 98.0%–102.0% on the anhydrous, solvent-free basis. Individual unspecified impurities are limited to NMT 0.10%, and total related substances to NMT 1.0%. Residual solvents are controlled under ICH Q3C with test execution per USP <467>; elemental impurities follow ICH Q3D and are measured by USP <232>/<233>. Water content by Karl Fischer is accepted at NMT 1.0% for oral powder grades and NMT 0.5% for injectable-grade material. Those water limits are not arbitrary: excess moisture can plasticize amorphous regions and accelerate hydrolytic degradation; for injectable-grade material, higher water content can increase the risk of sub-visible particulate formation and pressure excursions during terminal sterilisation. Chiral purity is confirmed by chiral HPLC, and X-ray powder diffraction is used to verify the crystalline phase against a reference diffractogram.

Material intended for tablet and capsule processing is usually milled or air-jet classified to a controlled particle size range because rimegepant free base has dissolution-rate-limited absorption. Coarse particles above 100 µm may reduce dissolution rate and increase variability under USP <711> testing. Fine particles below 10 µm can raise electrostatic adhesion, reduce flow, and cause punch sticking on rotary tablet presses. A bimodal distribution with D10 ≥10 µm and D90 ≤100 µm is therefore maintained for many oral grades; air-jet milling with inert nitrogen is used to limit moisture uptake and avoid thermal softening. The milled powder is then blended with disintegrant, diluent, and lubricant. Flow and compression behaviour are confirmed on formulation-specific blends using USP <1174> powder flow testing and a rotary tablet press equipped with compaction force monitoring. The granule route may be used when direct compression does not provide sufficient content uniformity or when the final blend density must be increased for capsule filling.

What Limits Direct Compression and Encapsulation Throughput?

Rimegepant API is a low-dose active; commercial oral products may deliver 75 mg of the free base equivalent from the sulfate salt. At this dose, tablet content uniformity under USP <905> is sensitive to particle size distribution and segregation during hopper discharge. Direct compression is feasible when the API is pre-blended with a carrier such as microcrystalline cellulose and croscarmellose sodium before final blending. If the API is not geo-mixed, low-drug-content areas can occur because the fine API adheres to the blender wall or to coarse excipient particles. Capsule filling on an automatic dosator machine requires consistent plug density; granulation may be required to reduce the angle of repose and increase bulk density. Dry granulation with roller compaction or wet granulation with aqueous binder can be used, but the low solubility of rimegepant free base means that wet massing may require a surfactant or sodium lauryl sulfate to improve wettability. The choice of granulation method is made after evaluating the moisture sensitivity of the salt, because amorphous content generated during milling can recrystallize during wet granulation and alter dissolution. Published data for this specific configuration is limited; development batches are therefore used to define the granulation end-point and drying profile.

For granule-filled sachets or sprinkle formulations, the API is typically granulated with sugar alcohols or mannitol to support rapid dispersion in water. Particle size after granulation is controlled by sieve analysis per USP <786>, and moisture content is kept below 1.0% to prevent sticking during sachet filling. In oral solids, the free base is often converted to the sulfate salt or purchased as the sulfate; salt factor calculations must be applied when weighing to ensure the label claim matches the free base equivalent. The sulfate salt has different powder flow and electrostatic behaviour than the free base, so the material code and certificate of analysis must clearly state whether batch input is expressed on the free base or salt basis.

When an Injectable Presentation Is Required, Which Parenteral-Grade Controls Become Rate-Limiting?

For injectable formulation, the API must meet the oral-grade chemical purity envelope plus bacterial endotoxin and bioburden controls. Endotoxin limits are calculated from the maximum adult dose per kilogram using the K/M formula in USP <85>; the limit cannot be assigned without the final clinical dose, route, and patient body weight. The API is dissolved in an appropriate vehicle and then sterile-filtered through a 0.22 µm membrane; filter compatibility must be demonstrated because hydrophobic active pharmaceutical ingredients can adsorb to polyvinylidene fluoride or polyethersulfone filters. Sub-visible particulate matter is tested on the finished solution per USP <788>, and container closure integrity is evaluated under USP <1207>. For an injectable product, the API water content is typically reduced to ≤0.5%, and the material is handled in an ISO 7 or better environment to limit bioburden ingress. If the formulation is intended for intravenous administration, pH adjustment and osmolality must be considered; rimegepant free base has low aqueous solubility, so solubilisation strategies such as pH adjustment with a buffering agent or a co-solvent system are evaluated. Published data for this specific configuration is limited, and no harmonized monograph for rimegepant injection is publicly referenced.

If the injectable is a simple solution rather than a liposomal or suspension product, the API must dissolve completely at the target concentration. Solubility screens in phosphate-buffered saline at pH 7.4 and citrate buffer at pH 3.0 are used to select the vehicle. Because rimegepant free base contains basic nitrogen centres, lower pH may improve solubility through protonation; however, pH below 2.0 may accelerate hydrolysis of susceptible functional groups. Stressed solution studies under ICH Q1B are used to confirm that the formulated solution does not generate new degradation products above the reporting threshold of 0.10%. The final injectable is filtered through a 0.22 µm sterilising-grade membrane and filled into glass vials with nitrogen overlay if oxygen sensitivity is observed.

Compared with triptan active ingredients used in migraine therapy, rimegepant does not depend on 5-HT1B/1D receptor-mediated vasoconstriction; this pharmacological difference does not alter powder flow but changes the safety assessment during injectable formulation because vascular adverse-effect studies are replaced by CGRP blockade monitoring. Among the gepant class, rimegepant is distinguished by its molecular weight of 534.56 g/mol and its use as a sulfate salt in the commercial orally disintegrating tablet. Ubrogepant and atogepant have different molecular structures and solid-state requirements; direct comparison of tableting and encapsulation performance among these APIs is not supported by public manufacturing data. The formulation difference is more evident at the finished dosage form: rimegepant is supplied as an orally disintegrating tablet, while other gepants may be presented as conventional immediate-release tablets. Unlike monoclonal antibody CGRP antagonists, rimegepant is a small molecule that can be processed by conventional oral solid dosage unit operations and, if formulated appropriately, by aseptic filtration. This difference does not imply therapeutic superiority; it changes pharmaceutical handling, analytical testing, and supply chain stability requirements. For compounding pharmacies or pharmaceutical manufacturers, the key specification difference is that rimegepant requires strict control of crystalline form and particle size, but comparative dissolution or processability data against ubrogepant and atogepant are limited in the public literature.

Regulatory Alignment Cannot Replace Stability-Sensitive Handling

The API is supported by a regulatory starting point rather than a final dosage-form approval. Material release follows ICH Q7 for active substances, and specification selection follows ICH Q6A. Stability testing is conducted under ICH Q1A; photostability is assessed under ICH Q1B because the molecule contains fluorinated aromatic rings that may be sensitive to light. The material should be stored in tightly closed containers at controlled room temperature, 20–25 °C with excursions to 15–30 °C per USP <659>, and protected from moisture. For injectable-grade material, single-use sampling and split-gown handling are used to preserve the low bioburden state. Incompatibility with strong oxidising agents is expected due to the presence of amine and heteroaromatic moieties; specific excipient compatibility data for rimegepant with mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate is established in formulation development but not fully published in compendial sources.